ES2155932T3 - Metodos y composiciones para la terapia genica para el tratamiento de defectos en el metabolismo de las lipoproteinas. - Google Patents

Metodos y composiciones para la terapia genica para el tratamiento de defectos en el metabolismo de las lipoproteinas.

Info

Publication number
ES2155932T3
ES2155932T3 ES96909592T ES96909592T ES2155932T3 ES 2155932 T3 ES2155932 T3 ES 2155932T3 ES 96909592 T ES96909592 T ES 96909592T ES 96909592 T ES96909592 T ES 96909592T ES 2155932 T3 ES2155932 T3 ES 2155932T3
Authority
ES
Spain
Prior art keywords
treatment
vector
lipoproteins
metabolism
defects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96909592T
Other languages
English (en)
Inventor
James M Wilson
Karen Kozarsky
Jerome Strauss Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Pennsylvania Penn filed Critical University of Pennsylvania Penn
Application granted granted Critical
Publication of ES2155932T3 publication Critical patent/ES2155932T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA INVENCION PROPORCIONA UN VECTOR VIRICO RECOMBINANTE QUE COMPRENDE EL ADN DE, O CORRESPONDIENTE A, AL MENOS UNA PORCION DEL GENOMA DE UN ADENOVIRUS, PORCION QUE ES CAPAZ DE INFECTAR UNA CELULA HEPATICA; Y UN GEN RECEPTOR DE VLDL HUMANA UNIDO OPERATIVAMENTE A SECUENCIAS REGULADORAS QUE DIRIGEN SU EXPRESION. EL VECTOR ES CAPAZ DE EXPRESAR EL PRODUCTO DEL GEN DEL RECEPTOR VLDL NORMAL EN CELULAS HEPATICAS IN VIVO O IN VITRO. ESTE VECTOR VIRICO ES UTIL EN EL TRATAMIENTO DE TRASTORNOS METABOLICOS CAUSADOS POR LA ACUMULACION DE LDL EN PLASMA, COMO HIPERCOLESTEROLEMIA FAMILIAR O HIPERLIPIDEMIA FAMILIAR COMBINADA.
ES96909592T 1995-02-24 1996-02-23 Metodos y composiciones para la terapia genica para el tratamiento de defectos en el metabolismo de las lipoproteinas. Expired - Lifetime ES2155932T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/393,734 US5652224A (en) 1995-02-24 1995-02-24 Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism

Publications (1)

Publication Number Publication Date
ES2155932T3 true ES2155932T3 (es) 2001-06-01

Family

ID=23556020

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96909592T Expired - Lifetime ES2155932T3 (es) 1995-02-24 1996-02-23 Metodos y composiciones para la terapia genica para el tratamiento de defectos en el metabolismo de las lipoproteinas.

Country Status (13)

Country Link
US (4) US5652224A (es)
EP (1) EP0811074B1 (es)
JP (1) JP3868489B2 (es)
AT (1) ATE199099T1 (es)
AU (1) AU696979B2 (es)
CA (1) CA2213254C (es)
DE (1) DE69611753T2 (es)
DK (1) DK0811074T3 (es)
ES (1) ES2155932T3 (es)
GR (1) GR3035812T3 (es)
MX (1) MX9706485A (es)
PT (1) PT811074E (es)
WO (1) WO1996026286A1 (es)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962322A (en) * 1996-11-15 1999-10-05 Massachusetts Institute Of Technology Methods for modulation of cholesterol transport
DE69534166T2 (de) * 1994-10-28 2006-03-09 Trustees Of The University Of Pennsylvania Rekombinanter adenovirus und methoden zu dessen verwendung
US6924128B2 (en) * 1994-12-06 2005-08-02 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5652224A (en) * 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
US6265212B1 (en) 1995-06-15 2001-07-24 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6783980B2 (en) * 1995-06-15 2004-08-31 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
IL160406A0 (en) * 1995-06-15 2004-07-25 Crucell Holland Bv A cell harbouring nucleic acid encoding adenoritus e1a and e1b gene products
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
EP0892643B2 (en) * 1996-03-20 2009-09-02 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
DE19620687A1 (de) * 1996-05-22 1997-11-27 Centeon Pharma Gmbh Neuer adenoviraler Vektor für den Transfer humaner Gene in vivo
US6989264B2 (en) * 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6346415B1 (en) * 1997-10-21 2002-02-12 Targeted Genetics Corporation Transcriptionally-activated AAV inverted terminal repeats (ITRS) for use with recombinant AAV vectors
AU3072799A (en) 1998-03-19 1999-10-11 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
DE69918090T2 (de) * 1998-04-24 2005-06-16 University Of Florida, Gainesville Rekombinanter adeno-assoziierter viraler vektor, der alpha-1 antitrypsin kodiert, zur gentherapie
AU5819599A (en) 1998-09-11 2000-04-03 Regents Of The University Of California, The Recombinant adenovirus for tissue specific expression in heart
US6406861B1 (en) 1998-10-07 2002-06-18 Cell Genesys, Inc. Methods of enhancing effectiveness of therapeutic viral immunogenic agent administration
US6893865B1 (en) 1999-04-28 2005-05-17 Targeted Genetics Corporation Methods, compositions, and cells for encapsidating recombinant vectors in AAV particles
FR2794771B1 (fr) * 1999-06-11 2001-08-10 Aventis Pharma Sa Adenovirus recombinants codant pour le transporteur specifique de l'iode (nis)
EP2213743A1 (en) 2000-04-12 2010-08-04 Human Genome Sciences, Inc. Albumin fusion proteins
JP2004536579A (ja) 2001-04-13 2004-12-09 ヒューマン　ジノーム　サイエンシーズ，　インコーポレイテッド 血管内皮増殖因子２
AU2002308540A1 (en) * 2001-05-01 2002-11-11 Genstar Therapeutics Corp. Mini-adenoviral vector and methods of using same
ATE434404T1 (de) * 2001-08-30 2009-07-15 Sinai School Medicine Alternativ gesplicter zirkulierender gewebefaktor
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
AU2002364586A1 (en) 2001-12-21 2003-07-30 Delta Biotechnology Limited Albumin fusion proteins
US7582290B2 (en) * 2002-04-08 2009-09-01 The Johns Hopkins University Packaging cell line for diphtheria toxin expressing non-replicating adenovirus
AU2003269884A1 (en) * 2002-05-22 2003-12-22 Incyte Corporation Receptors and membrane-associated proteins
JP2006518997A (ja) * 2003-01-21 2006-08-24 ブリストル−マイヤーズ　スクイブ　カンパニー 新規アシルコエンザイムａ：モノアシルグリセロールアシルトランスフェラーゼ−３（ｍｇａｔ３）をコードするポリヌクレオチドおよびその用途
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US20060039949A1 (en) * 2004-08-20 2006-02-23 Nycz Jeffrey H Acetabular cup with controlled release of an osteoinductive formulation
US20060045902A1 (en) * 2004-09-01 2006-03-02 Serbousek Jon C Polymeric wrap for in vivo delivery of osteoinductive formulations
US20060057184A1 (en) * 2004-09-16 2006-03-16 Nycz Jeffrey H Process to treat avascular necrosis (AVN) with osteoinductive materials
US8414907B2 (en) * 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US9119901B2 (en) * 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US20070179618A1 (en) * 2006-01-31 2007-08-02 Sdgi Holdings, Inc. Intervertebral prosthetic disc
US20070179615A1 (en) * 2006-01-31 2007-08-02 Sdgi Holdings, Inc. Intervertebral prosthetic disc
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2533629B1 (en) 2010-02-11 2018-11-28 Recombinetics, Inc. Methods and materials for producing transgenic artiodactyls
US10920242B2 (en) 2011-02-25 2021-02-16 Recombinetics, Inc. Non-meiotic allele introgression
WO2014120975A1 (en) 2013-02-01 2014-08-07 California Institute Of Technology Antibody-mediated immunocontraception
SMT202000531T1 (it) 2014-03-09 2020-11-10 Univ Pennsylvania Composizioni utili in trattamento di deficit di ornitina transcarbamilasi(otc)
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
EP4418213A3 (en) 2014-10-06 2024-11-20 Dexcom, Inc. System and method for data analytics and visualization
RU2716991C2 (ru) 2014-11-05 2020-03-17 Вояджер Терапьютикс, Инк. Полинуклеотиды aadc для лечения болезни паркинсона
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2016077687A1 (en) 2014-11-14 2016-05-19 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
US10966414B2 (en) 2015-05-26 2021-04-06 California Institute Of Technology Population control using engineered translocations
EP3384035A4 (en) 2015-12-02 2019-08-07 Voyager Therapeutics, Inc. ASSAYS FOR THE DETECTION OF AAV-NEUTRALIZING ANTIBODIES
US11020160B2 (en) 2016-03-21 2021-06-01 Warsaw Orthopedic, Inc. Surgical injection system and method
US10709814B2 (en) 2016-04-22 2020-07-14 Warsaw Orthopedic, Inc. Osteoimplant comprising an insoluble fibrous polymer
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
KR102427379B1 (ko) 2016-05-18 2022-08-02 보이저 테라퓨틱스, 인크. 헌팅톤 질환을 치료하기 위한 조성물 및 방법
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
WO2018044933A1 (en) 2016-08-30 2018-03-08 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
IL301059B2 (en) * 2017-04-21 2026-04-01 Prec Biosciences Inc Engineered nucleosides specific for recognition sequences in the PCSK9 gene
JP2020518259A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． ハンチントン病治療組成物および方法
JP2020518258A (ja) 2017-05-05 2020-06-25 ボイジャー セラピューティクス インコーポレイテッドＶｏｙａｇｅｒ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 筋萎縮性側索硬化症（ａｌｓ）治療組成物および方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
EP3808849A1 (en) 2017-08-03 2021-04-21 Voyager Therapeutics, Inc. Compositions and methods for delivery of aav
AU2018338728B2 (en) 2017-09-29 2025-01-02 Centre National De La Recherche Scientifique (Cnrs) Rescue of central and peripheral neurological phenotype of Friedreich's Ataxia by intravenous delivery
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
EP3697908A1 (en) 2017-10-16 2020-08-26 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
KR20210019996A (ko) 2018-05-15 2021-02-23 보이저 테라퓨틱스, 인크. 파킨슨병의 치료를 위한 조성물 및 방법
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
EP3856762A1 (en) 2018-09-28 2021-08-04 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
US11965172B2 (en) 2018-11-05 2024-04-23 California Institute Of Technology DNA sequence modification-based gene drive
WO2020160508A1 (en) 2019-01-31 2020-08-06 Oregon Health & Science University Methods for using transcription-dependent directed evolution of aav capsids
KR20230002594A (ko) * 2020-04-29 2023-01-05 살리오젠 테라퓨틱스 인코포레이티드 가족성 고콜레스테롤혈증 및 상승된 저밀도 지단백질 콜레스테롤의 치료를 위한 조성물 및 방법
WO2022165313A1 (en) 2021-02-01 2022-08-04 Regenxbio Inc. Gene therapy for neuronal ceroid lipofuscinoses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4658019A (en) * 1979-04-26 1987-04-14 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human T cells
US5139941A (en) * 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US5166320A (en) * 1987-04-22 1992-11-24 University Of Connecticut Carrier system and method for the introduction of genes into mammalian cells
US5580776A (en) * 1988-02-05 1996-12-03 Howard Hughes Medical Institute Modified hepatocytes and uses therefor
WO1989007136A2 (en) 1988-02-05 1989-08-10 Whitehead Institute For Biomedical Research Modified hepatocytes and uses therefor
ATE140483T1 (de) * 1988-11-10 1996-08-15 Genetics Inst Natürlicher killerzellen-stimulationsfaktor
US5240846A (en) * 1989-08-22 1993-08-31 The Regents Of The University Of Michigan Gene therapy vector for cystic fibrosis
WO1991018088A1 (en) * 1990-05-23 1991-11-28 The United States Of America, Represented By The Secretary, United States Department Of Commerce Adeno-associated virus (aav)-based eucaryotic vectors
CA2059824A1 (en) * 1991-02-26 1992-08-27 Thomas M. Aune Hybridomas and monoclonal antibodies that inhibit anti-cd3-stimulated t cell proliferation
CA2580812A1 (en) * 1991-06-27 1993-01-07 Bristol-Myers Squibb Company Ctla4 receptor, fusion proteins containing it and uses thereof
IL104684A0 (en) * 1992-02-14 1993-06-10 Bristol Myers Squibb Co The cd40cr receptor and ligands therefor
AU5457294A (en) * 1992-10-29 1994-05-24 Board Of Regents, The University Of Texas System Adenovirus-mediated ldl receptor gene transfer and targeting
EP1024198A3 (en) * 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
AU6133394A (en) * 1993-02-09 1994-08-29 Scripps Research Institute, The Targeting and delivery of genes and antiviral agents into cells by the adenovirus penton
FR2704556B1 (fr) 1993-04-30 1995-07-13 Rhone Poulenc Rorer Sa Virus recombinants et leur utilisation en thérapie génique.
SK282843B6 (sk) 1993-07-13 2002-12-03 Rhone-Poulenc Rorer S. A. Defektný rekombinantný adenovírus a farmaceutický prostriedok s jeho obsahom
US6686200B1 (en) * 1993-08-31 2004-02-03 Uab Research Foundation Methods and compositions for the large scale production of recombinant adeno-associated virus
US5750367A (en) * 1993-11-08 1998-05-12 Baylor College Of Medicine Human and mouse very low density lipoprotein receptors and methods for use of such receptors
US5856152A (en) * 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
US5872154A (en) * 1995-02-24 1999-02-16 The Trustees Of The University Of Pennsylvania Method of reducing an immune response to a recombinant adenovirus
US5652224A (en) 1995-02-24 1997-07-29 The Trustees Of The University Of Pennsylvania Methods and compositions for gene therapy for the treatment of defects in lipoprotein metabolism
JP2002514899A (ja) 1996-03-04 2002-05-21 ターゲティッド ジェネティックス コーポレイション 組換えａａｖベクターを用いて血管中の細胞を形質導入するための方法
US7111111B2 (en) * 2003-07-08 2006-09-19 Broadcom Corporation Scheme for optimal settings for DDR interface

Also Published As

Publication number Publication date
DE69611753T2 (de) 2001-08-09
AU696979B2 (en) 1998-09-24
CA2213254A1 (en) 1996-08-29
JPH11500623A (ja) 1999-01-19
EP0811074B1 (en) 2001-02-07
US6887463B2 (en) 2005-05-03
EP0811074A1 (en) 1997-12-10
WO1996026286A1 (en) 1996-08-29
JP3868489B2 (ja) 2007-01-17
DE69611753D1 (de) 2001-03-15
US20050112103A1 (en) 2005-05-26
US5652224A (en) 1997-07-29
US6174527B1 (en) 2001-01-16
CA2213254C (en) 2009-05-12
US20020182182A1 (en) 2002-12-05
US7306794B2 (en) 2007-12-11
ATE199099T1 (de) 2001-02-15
PT811074E (pt) 2001-07-31
DK0811074T3 (da) 2001-06-18
AU5303196A (en) 1996-09-11
GR3035812T3 (en) 2001-07-31
MX9706485A (es) 1997-11-29

Similar Documents

Publication Publication Date Title
ES2155932T3 (es) Metodos y composiciones para la terapia genica para el tratamiento de defectos en el metabolismo de las lipoproteinas.
Sandonà et al. Mesenchymal stromal cells and their secretome: new therapeutic perspectives for skeletal muscle regeneration
Matthews et al. Analysis of αSMA‐labeled progenitor cell commitment identifies notch signaling as an important pathway in fracture healing
Thiagarajan et al. Osteogenic programming of human mesenchymal stem cells with highly efficient intracellular delivery of RUNX2
Zhang et al. Regulation of mesenchymal stem cell osteogenic differentiation by glucocorticoid-induced leucine zipper (GILZ)
Palmer et al. Gene-induced chondrogenesis of primary mesenchymal stem cells in vitro
Simic et al. SIRT1 regulates differentiation of mesenchymal stem cells by deacetylating β‐catenin
Tang et al. Protein deubiquitinase USP7 is required for osteogenic differentiation of human adipose-derived stem cells
Johnson et al. The Nrf2–ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration
Baker et al. Caveolin‐1 regulates proliferation and osteogenic differentiation of human mesenchymal stem cells
Lin et al. Polybrene inhibits human mesenchymal stem cell proliferation during lentiviral transduction
Dokka et al. High-efficiency gene transfection of macrophages by lipoplexes
Heo et al. Distal-less homeobox 5 is a master regulator of the osteogenesis of human mesenchymal stem cells
Matre et al. CRISPR/Cas9-based dystrophin restoration reveals a novel role for dystrophin in bioenergetics and stress resistance of muscle progenitors
Schoppa et al. Osteoblast lineage Sod2 deficiency leads to an osteoporosis-like phenotype in mice
Rocha et al. Extracellular environment contribution to astrogliosis—lessons learned from a tissue engineered 3D model of the glial scar
Aisha et al. Orbital fluid shear stress promotes osteoblast metabolism, proliferation and alkaline phosphates activity in vitro
Calzia et al. Characterization of C2C12 cells in simulated microgravity: Possible use for myoblast regeneration
Choi et al. Rapid induction of osteogenic markers in mesenchymal stem cells by adipose-derived stromal vascular fraction cells
Azechi et al. 5-Aza-2-deoxycytidine, a DNA methyltransferase inhibitor, facilitates the inorganic phosphorus-induced mineralization of vascular smooth muscle cells
Fu et al. Adipogenic differentiation potential of adipose‐derived mesenchymal stem cells from ovariectomized mice
Hoare et al. Enhanced lipoplex‐mediated gene expression in mesenchymal stem cells using reiterated nuclear localization sequence peptides
Yang et al. Sox‐9 facilitates differentiation of adipose tissue‐derived stem cells into a chondrocyte‐like phenotype in vitro
Qu et al. Sirtuin1 promotes osteogenic differentiation through downregulation of peroxisome proliferator-activated receptor γ in MC3T3-E1 cells
Luo et al. Effect of microRNA-20a on osteogenic differentiation of human adipose tissue-derived stem cells

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 811074

Country of ref document: ES